Comparison of Bioartificial Pancreas Performance in the Bone Marrow Cavity and Intramuscular Space

Kai Chiang Yang, Chang Chin Wu, Zhi Qi, Jung Chih Chen, Shoichiro Sumi, Feng Huei Lin

研究成果: 雜誌貢獻文章

9 引文 (Scopus)

摘要

Background and Aims: Bone marrow with a widely distributed and well-vascularized microenvironment that is capable of sustaining grafts is a potential site for islet transplantation. The femur bone marrow cavity offers sufficient space that may also receive the implantation of bioartificial pancreas (BAP). Methods: Mouse insulinoma cells encapsulating in agarose gel were further enclosed in a calcium phosphate cement chamber to create a BAP. BAPs implanted into the femur bone marrow cavity of diabetics were compared with those implanted in the intramuscular space. Blood glucose level and C-peptide were determined perioperatively. Results: The blood glucose level of the diabetics receiving BAPs in the intramuscular space decreased from 413 ± 24 to 285 ± 47 mg/dL at 1 day post-surgery. However, the blood glucose level returned to 398 ± 35 mg/dL with undetectable serum C-peptide at 2 weeks postoperatively that reveals implant failure. The blood glucose level of diabetics receiving BAPs into the femur bone marrow cavity decreased from 422 ± 32 to 247 ± 52 mg/dL and maintained in the range of 288 ± 47 mg/dL during the experimental period with an increase in C-peptide level from 6.1 ± 2.8 to 104.7 ± 16.4 pmol/L. Conclusions: This preliminary study indicates that the effectiveness of BAPs transplanted into the femur bone marrow cavity is superior to that implanted in the intramuscular space, which reveals the bone marrow may be a potential receptor site for the BAP transplantation.
原文英語
頁(從 - 到)151-153
頁數3
期刊Archives of Medical Research
41
發行號3
DOIs
出版狀態已發佈 - 四月 2010
對外發佈Yes

指紋

Pancreas
Bone Marrow
Femur
Blood Glucose
C-Peptide
Pancreas Transplantation
Islets of Langerhans Transplantation
Insulinoma
Ambulatory Surgical Procedures
Sepharose
Gels
Transplants
Serum

ASJC Scopus subject areas

  • Medicine(all)

引用此文

Comparison of Bioartificial Pancreas Performance in the Bone Marrow Cavity and Intramuscular Space. / Yang, Kai Chiang; Wu, Chang Chin; Qi, Zhi; Chen, Jung Chih; Sumi, Shoichiro; Lin, Feng Huei.

於: Archives of Medical Research, 卷 41, 編號 3, 04.2010, p. 151-153.

研究成果: 雜誌貢獻文章

Yang, Kai Chiang ; Wu, Chang Chin ; Qi, Zhi ; Chen, Jung Chih ; Sumi, Shoichiro ; Lin, Feng Huei. / Comparison of Bioartificial Pancreas Performance in the Bone Marrow Cavity and Intramuscular Space. 於: Archives of Medical Research. 2010 ; 卷 41, 編號 3. 頁 151-153.
@article{c1c5dcb419104fefbd0ee7d7b80a89ba,
title = "Comparison of Bioartificial Pancreas Performance in the Bone Marrow Cavity and Intramuscular Space",
abstract = "Background and Aims: Bone marrow with a widely distributed and well-vascularized microenvironment that is capable of sustaining grafts is a potential site for islet transplantation. The femur bone marrow cavity offers sufficient space that may also receive the implantation of bioartificial pancreas (BAP). Methods: Mouse insulinoma cells encapsulating in agarose gel were further enclosed in a calcium phosphate cement chamber to create a BAP. BAPs implanted into the femur bone marrow cavity of diabetics were compared with those implanted in the intramuscular space. Blood glucose level and C-peptide were determined perioperatively. Results: The blood glucose level of the diabetics receiving BAPs in the intramuscular space decreased from 413 ± 24 to 285 ± 47 mg/dL at 1 day post-surgery. However, the blood glucose level returned to 398 ± 35 mg/dL with undetectable serum C-peptide at 2 weeks postoperatively that reveals implant failure. The blood glucose level of diabetics receiving BAPs into the femur bone marrow cavity decreased from 422 ± 32 to 247 ± 52 mg/dL and maintained in the range of 288 ± 47 mg/dL during the experimental period with an increase in C-peptide level from 6.1 ± 2.8 to 104.7 ± 16.4 pmol/L. Conclusions: This preliminary study indicates that the effectiveness of BAPs transplanted into the femur bone marrow cavity is superior to that implanted in the intramuscular space, which reveals the bone marrow may be a potential receptor site for the BAP transplantation.",
keywords = "Bioartificial pancreas, Bone marrow cavity, Intramuscular space, Type 1 diabetes",
author = "Yang, {Kai Chiang} and Wu, {Chang Chin} and Zhi Qi and Chen, {Jung Chih} and Shoichiro Sumi and Lin, {Feng Huei}",
year = "2010",
month = "4",
doi = "10.1016/j.arcmed.2010.03.002",
language = "English",
volume = "41",
pages = "151--153",
journal = "Archives of Medical Research",
issn = "0188-4409",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Comparison of Bioartificial Pancreas Performance in the Bone Marrow Cavity and Intramuscular Space

AU - Yang, Kai Chiang

AU - Wu, Chang Chin

AU - Qi, Zhi

AU - Chen, Jung Chih

AU - Sumi, Shoichiro

AU - Lin, Feng Huei

PY - 2010/4

Y1 - 2010/4

N2 - Background and Aims: Bone marrow with a widely distributed and well-vascularized microenvironment that is capable of sustaining grafts is a potential site for islet transplantation. The femur bone marrow cavity offers sufficient space that may also receive the implantation of bioartificial pancreas (BAP). Methods: Mouse insulinoma cells encapsulating in agarose gel were further enclosed in a calcium phosphate cement chamber to create a BAP. BAPs implanted into the femur bone marrow cavity of diabetics were compared with those implanted in the intramuscular space. Blood glucose level and C-peptide were determined perioperatively. Results: The blood glucose level of the diabetics receiving BAPs in the intramuscular space decreased from 413 ± 24 to 285 ± 47 mg/dL at 1 day post-surgery. However, the blood glucose level returned to 398 ± 35 mg/dL with undetectable serum C-peptide at 2 weeks postoperatively that reveals implant failure. The blood glucose level of diabetics receiving BAPs into the femur bone marrow cavity decreased from 422 ± 32 to 247 ± 52 mg/dL and maintained in the range of 288 ± 47 mg/dL during the experimental period with an increase in C-peptide level from 6.1 ± 2.8 to 104.7 ± 16.4 pmol/L. Conclusions: This preliminary study indicates that the effectiveness of BAPs transplanted into the femur bone marrow cavity is superior to that implanted in the intramuscular space, which reveals the bone marrow may be a potential receptor site for the BAP transplantation.

AB - Background and Aims: Bone marrow with a widely distributed and well-vascularized microenvironment that is capable of sustaining grafts is a potential site for islet transplantation. The femur bone marrow cavity offers sufficient space that may also receive the implantation of bioartificial pancreas (BAP). Methods: Mouse insulinoma cells encapsulating in agarose gel were further enclosed in a calcium phosphate cement chamber to create a BAP. BAPs implanted into the femur bone marrow cavity of diabetics were compared with those implanted in the intramuscular space. Blood glucose level and C-peptide were determined perioperatively. Results: The blood glucose level of the diabetics receiving BAPs in the intramuscular space decreased from 413 ± 24 to 285 ± 47 mg/dL at 1 day post-surgery. However, the blood glucose level returned to 398 ± 35 mg/dL with undetectable serum C-peptide at 2 weeks postoperatively that reveals implant failure. The blood glucose level of diabetics receiving BAPs into the femur bone marrow cavity decreased from 422 ± 32 to 247 ± 52 mg/dL and maintained in the range of 288 ± 47 mg/dL during the experimental period with an increase in C-peptide level from 6.1 ± 2.8 to 104.7 ± 16.4 pmol/L. Conclusions: This preliminary study indicates that the effectiveness of BAPs transplanted into the femur bone marrow cavity is superior to that implanted in the intramuscular space, which reveals the bone marrow may be a potential receptor site for the BAP transplantation.

KW - Bioartificial pancreas

KW - Bone marrow cavity

KW - Intramuscular space

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=77953504488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953504488&partnerID=8YFLogxK

U2 - 10.1016/j.arcmed.2010.03.002

DO - 10.1016/j.arcmed.2010.03.002

M3 - Article

C2 - 20682171

AN - SCOPUS:77953504488

VL - 41

SP - 151

EP - 153

JO - Archives of Medical Research

JF - Archives of Medical Research

SN - 0188-4409

IS - 3

ER -